Overview: Mucopolysaccharidosis Screen TestIntroduction: The Mucopolysaccharidosis Screen Test screens for mucopolysaccharidosis to diagnose metabolic disorders, causing developmental delays. Following 2023 NORD guidelines, it uses biochemistry methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical pathology for patients with suspected lysosomal storage disorders.
Other Names: MPS Screen Assay, Lysosomal Storage Disease Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards for diagnostic accuracy.
Historical Milestone: MPS screening began in the 1970s with lysosomal storage research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Screens for mucopolysaccharidosis to diagnose metabolic disorders, guides treatment, and evaluates patients with developmental delays.
Test Parameters: 1. Mucopolysaccharidosis Screen
Pretest Condition: No fasting required. Collect urine. Report history of developmental delays or organ enlargement.
Specimen: Urine (sterile container, 5-20 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document developmental delays, organ enlargement, or family history of lysosomal storage diseases. Include current medications.
Consent: Written consent required, detailing the tests purpose, MPS implications, and risks of urine collection.
Procedural Considerations: Uses biochemistry methods to screen for mucopolysaccharidosis in urine. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for metabolic disorder screening.
Factors Affecting Result Accuracy: Contamination or improper sample storage can affect results. Dilute urine may reduce sensitivity.
Clinical Significance: Positive MPS screen suggests lysosomal storage disorder, guiding further enzyme testing. Negative results may require genetic testing.
Specialist Consultation: Consult a geneticist or metabolic specialist for result interpretation and treatment planning.
Additional Supporting Tests: Enzyme activity assays, genetic sequencing, or skeletal imaging to confirm MPS diagnosis.
Test Limitations: Broad screening may miss specific MPS types; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD MPS Guidelines, 2023; Journal of Inherited Metabolic Disease, Muenzer J, 2022.
